3 years ago

120 - D Serrani - Marzo de 2020

  • Text
  • Serrani
  • Antipsicoticos
  • Antipsicoticosatipicos
  • Sintomasresiduales
  • Depresionresistente
Beneficio clínico y funcional de antipsicóticos atípicos en síntomas residuales de depresión resistente. Parte 1

Dr. Daniel

Dr. Daniel Serrani ly to fluoxetine. J. Clin. Psychiatry 1999, 60, 221–225. • 7. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized trials in MDD. Eur Neuropsychopharmacol. 2009; 19(1): 34-40. • 8. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and non-response in primary care treatment of depression. Arch Intern Med. 2004; 164: 1197-1204. • 9 .Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus acrossclass switches. Biol Psychiatry 2008; 63:699. • 10. Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol Psychiatry. 2004; 56:46-53. • 11. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005;25:336-341. • 12. Trivedi MH, Fava M, Wisniewski SR, et al.; for the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252. • 13. Israel J. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals 2010, 3: 2426-2440. • 14. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W & Rice JA. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of affective disorders, 1998; 50(2- 3), 97-108. • 15. Kennedy N & Paykel E. Residual symptoms at remission from depression: impact on long-term outcome. Journal of affective disorders; 2004; 135-144. • 16. Conradi HJ, Ormel J & De Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological medicine, 2011; 1165-1174. • 17. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J & Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychological medicine 1995, 25(6): 1171-1180. • 18. Romera I, Pérez V, Ciudad A, Caballero L, Roca M, Polavieja P, Gilaberte I. Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis BMC Psychiatry 2013, 13:51. • 19. Hiranyatheb T, Nakawiro D, Wongpakaran T, Wongpakaran N, Bookkamana P, Pinyopornpanish M et al The impact of residual symptoms on relapse and quality of life among Thai depressive patients, Neuropsychiatric Disease and Treatment, 2016;12: 3175–3181. • 20. Roca M, García M, García J, Vives M, Armengol S, García M, Asensio D, Gili M. Clinical differences between early and late remission in depressive patients.J Affect Disord. 2011; 134(1-3):235-41. • 21. Lewis L, Judd M; Schettler P, Rush J. A Brief Clinical Tool to Estimate Individual Patients’ Risk of Depressive Relapse Following Remission: Proof of Concept Am J Psychiatry 2016; 173: 11. • 22. Derogatis LR, Lipman RS, Covi L: SCL- 90: an outpatient psychiatric rating scale: preliminary report. Psychopharmacol Bull 1973; 9:13–28. • 23. Soldatos CR, Dikeos DG y Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. Journal of psychosomatic research, 2000; 48(6): 555- 560. • 24. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med, 2001; 2(4): 297–307. • 25. Pittsburgh Sleep Quality Index (Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res, 1989; 28(2): 193–213. • 26. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998, 86:102–106. • 27. Gómez-Benito J, Guilera G, Pino Ó, Rojo E, Tabarés-Seisdedos R, Safont G. Spanish Working Group in Cognitive Function (2013). The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. BMC psychiatry, 13, 127. • 28. Rosa AR, Mercadé C, Sánchez-Moreno J, Solé B, Mar Bonnin CD, Torrent C, Grande I, Sugranyes G, Popovic D, Salamero M, et al. Cognitive Complaints in Bipolar Disorder Rating Assessment. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J Affect Disord. 2013; 150(1):29-36. • 29. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012; 140(2):113–24. • 30). Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48. • 31. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med. 1998; 28(5): 1027–38. • 32. Kennedy N, Foy K, Sherazi R, McDonough M, McKeon P. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007; 9(1–2):25–37. • 33. Gonda X, Pompili M, Serafini G, Carvalho AF, Rihmer Z, Dome P. The role of cognitive dysfunction in the symptoms and remission from depression. Annals of general psychiatry, 2015; 14(1): 27). • 34. Sheehan DV, Harnett-Sheehan K & Raj BA. The measurement of disability. International Clinical Psychopharmacology, 1996; 11 (Suppl 3): 89-95. • 35. Mundt JC, Marks IM, Shear MK y Greist JM. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. British Journal of Psychiatry 2002; 180(5): 461-464. • 36. Endicott J, Nee J, Harrison W y Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology bulletin 1993. ;29(2):321-6. • 37. Badia X, Roset M, Montserrat S, Herdman M y Segura A. The Spanish version of EuroQol: a description and its applications. European Quality of Life scale 1999. Medicina clínica, 112, 79-85. • 38. Zimmerman M, Martinez JH, Attiullah N, Friedman M, Toba C, Boerescu DA & Ragheb M. A new type of scale for determining remission from depression: the remission from depression questionnaire. J Psychiatr Res, 2013; 47(1): 78-82A. • 39. Augustovski FA, Lewin G, Elorrio EG, Rubinstein A. The Argentine-Spanish SF-36 Health Survey. J Clin, 2008; 61(12): 1279-84. • 40. Spielberger C. Manual for the State-Trait Anxiety Inventory. rev. ed. Consulting Psychologists Press; Palo Alto (CA): 1983. • 41. García J, Zamorano E, Ruiz MA, Pardo A, Pérez M, López V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes, 2010; 20(8): 8. • 42. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56:893–7. • 43. Bech Per. The ABC profile of the HAM-D17. Brazilian Journal of Psychiatry 2011; 33(2), 109- 110. 30 // EDITORIAL SCIENS

Copied successfully!